Call
+918447748545

Published on: Apr 04, 2020
2 minute read
By: Dr Rajan Choudhary

THE CHALLENGES FACED IN MAKING A VACCINE FOR COVID-19 — Part 2

Previously we’ve seen the difficulties researches face in trying to make a vaccine. But even if we make a vaccine, that’s just half the battle. Viruses are unique because they can mutate, and they can mutate to astonishing degrees. In humans mutations to tiny parts of our DNA can cause severe diseases or even death. In viruses mutations can change their structure, making them more infective and giving them a new coat. It gives them a survival advantage, the ability to evade our immune system and make our vaccines ineffective. This is why we need a new flu vaccine every year.

If it takes months to a year to develop a vaccine, it will be based off the virus found in December 2019. By this time the virus may have spread and mutated to such a degree that it is not effective. This does not mean all the effort was for nothing. Going through the steps and understanding the issues faced with making a COVID-19 vaccine can make the process quicker for subsequent vaccines against its mutated versions.

https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away So Long to Develop a Vaccine

FAILURES FROM THE PAST

These issues were faced during the Ebola and Zika virus epidemics, and many large companies are understandably hesitant to develop vaccines for COVID-19. Ebola first broke out in 2014, and it was only in December 2019 that the first vaccine was approved for use by the European Commission and the United States. This is despite multiple large institutes in Canada and the UK working together to develop it.

13 different Ebola vaccine candidates had been identified soon after the outbreak, but none had been tested on humans. Unfortunately this is the most expensive part of development, and the area biopharmecuticals stand to loose the most money. Return on investments is also low, since epidemics usually take place in poorer countries, and the potential customers are unable to pay the high prices for these brand new treatments. It is an unfortunate realisation that research into medicines is driven by rich countries, for diseases that affect the rich.

https://newint.org/features/web-exclusive/2016/06/16/why-did-the-market-fail-to-produce-an-ebola-vaccine Ebola

WHERE ARE WE NOW?

This is all well and good, but what does it mean for COVID-19? We know we cannot rush a vaccine, because a poorly designed vaccine with unknown side effects can cause more harm than good, especially if given to children or the elderly. Currently the WHO are tracking 31 different attempts at making a COVID-19 vaccine, using different methods as discussed before. All of these are currently in the pre-clinical stage, focusing on isolating parts of the virus and creating a target the body will recognise and react to.

Researchers at the University of Queensland were one of the first to start using the genetic code of COVID-19, released openly by Chinese researchers. They have developed a test vaccine within 6 weeks using state-of-the-art genetic techniques, used for the first time. If animal models prove successful then human testing might begin within 6 months. In the pharmaceutical industry advancements this quick are almost unheard of.

Additionally over 293 clinical trials are taking place in China using existing drugs on the market. The advantage is we already know these drugs are safe to use in humans, but we are trying to work out if they will work against COVID-19. Some scientists are also looking at medications that were initially developed against SARS and MERS, but never completed because these outbreaks died down and the medication was no longer required.

https://www.aljazeera.com/news/2020/03/china-recovered-develop-effective-covid-19-treatments-200302082850237.html COVID-19 treatments

https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 WHO news

https://www.theverge.com/2020/2/28/21156385/covid-coronavirus-vaccine-treatment-moderna-remdesivir-research COVID-19 treatment

Its not all doom and gloom. Challenges drive innovation, and we are already benefitting from this. New forms of genetic sequencing, new methods for extracting viral proteins, new techniques in creating a vaccine. These innovations are already benefitting us on the drive to create an effective vaccine for COVID-19, and they will benefit us in the future when the next pandemic hits.

Dr Rajan Choudhary, Product Manager Second Medic UK

www.secondmedic.com

Read Blog

Difference Between Sadness and Depression: Understanding Normal Emotions vs Mental Illness

Feeling low or unhappy is a part of being human. However, not all low moods are the same. Many people confuse sadness with depression, which can delay proper support and treatment. Understanding the difference between sadness and depression is crucial for mental health awareness, early intervention and reducing stigma.

In India, mental health conditions are often misunderstood, with emotional distress frequently dismissed as temporary sadness.

What Is Sadness?

Sadness is a normal human emotion.

It usually occurs due to:

loss or disappointment
relationship issues
failure or stress
temporary life challenges

Sadness serves a psychological purpose, allowing individuals to process emotions and adapt.

Key Characteristics of Sadness

Sadness is:

situational
temporary
emotionally painful but manageable
responsive to support and positive events

A person experiencing sadness can still function, enjoy moments and feel hopeful.

What Is Depression?

Depression is a medical condition classified as a mood disorder.

It affects:

emotions
thinking patterns
behaviour
physical health

According to WHO, depression is one of the leading causes of disability worldwide.

Core Symptoms of Depression

Depression involves a combination of symptoms such as:

persistent low mood
loss of interest or pleasure
fatigue
sleep disturbances
appetite changes
feelings of worthlessness
difficulty concentrating

These symptoms last at least two weeks or longer.

Duration: A Key Difference

One major difference lies in duration.

Sadness:

lasts hours or days
improves with time

Depression:

lasts weeks or months
persists despite positive events

Duration helps distinguish emotional response from illness.

Impact on Daily Functioning

Sadness:

allows continuation of work and relationships
may reduce motivation temporarily

Depression:

interferes with work, studies and relationships
reduces self-care and productivity

Functional impairment is a defining feature of depression.

Emotional Experience: Sadness vs Depression

Sadness:

allows emotional range
moments of joy still occur

Depression:

creates emotional numbness
joy and interest disappear

People with depression often describe feeling empty rather than sad.

Physical Symptoms in Depression

Depression is not only emotional.

Physical symptoms include:

chronic fatigue
body aches
headaches
digestive issues

ICMR mental health studies highlight the physical burden of depression.

Thought Patterns and Self-Perception

Sadness:

thoughts remain realistic
self-worth is preserved

Depression:

negative self-talk dominates
feelings of guilt and worthlessness increase

These cognitive changes deepen emotional suffering.

Risk Factors for Depression

Factors increasing depression risk include:

chronic stress
trauma
family history
medical illnesses
hormonal changes

NFHS-5 data indicates rising mental health concerns among young adults.

Can Sadness Turn Into Depression?

Yes, prolonged or unresolved sadness can progress into depression.

This is more likely when:

stressors are ongoing
support systems are weak
coping mechanisms are limited

Early emotional support can prevent progression.

When to Seek Professional Help

Seek help if:

low mood lasts more than two weeks
daily functioning is affected
sleep and appetite are disturbed
thoughts of self-harm occur

Early care leads to better outcomes.

Treatment Differences

Sadness:

improves with rest, support and time

Depression:

requires psychotherapy
may need medication
benefits from structured care

WHO emphasises early treatment to reduce disability.

Role of Social Support

Support systems help both conditions but are essential for recovery.

Depression recovery improves with:

understanding family
supportive workplaces
accessible mental healthcare

Stigma reduction is key.

Mental Health Awareness in India

Mental health remains underdiagnosed in India.

NITI Aayog reports:

limited access to mental health services
low awareness
high stigma

Education helps bridge this gap.

Importance of Early Recognition

Recognising depression early:

prevents worsening
reduces suicide risk
improves quality of life

Delay increases suffering and complications.

Supporting Someone With Depression

Helpful actions include:

listening without judgement
encouraging professional help
avoiding minimising feelings

Compassion is more effective than advice.

Conclusion

Understanding the difference between sadness and depression is essential for emotional wellbeing and mental health care. Sadness is a natural, temporary response to life events, while depression is a serious medical condition that affects thoughts, emotions and daily functioning. Recognising the signs early and seeking appropriate help can prevent long-term suffering and promote recovery. Mental health deserves the same attention and care as physical health.

References

World Health Organization (WHO) – Depression and Mental Health Disorders
Indian Council of Medical Research (ICMR) – Mental Health Research and Burden
National Family Health Survey (NFHS-5) – Mental Health Indicators
Lancet – Depression, Disability and Public Health
NITI Aayog – National Mental Health Policy and Awareness Reports
Statista – Global and Indian Mental Health Trends

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.